Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA4 | P22748 | 3/20 | 0.52 |
| ▸ | CA6 | P23280 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27051913 | 0.86 | HTT (0.61) | TTRKDM4ECA12CA1CA2 | |
| SCHEMBL1029279 | 0.85 | PDE4A (0.59) | TTRKDM4ECA12CA1CA2 | |
| SCHEMBL3596045 | 0.84 | PKM (0.42) | KDM4EGAAMAPTPOLBHTT | |
| SCHEMBL30147631 | 0.82 | HTT (0.64) | TTRKDM4ECA12CA1CA2 | |
| SCHEMBL20042919 | 0.82 | HTT (0.64) | TTRKDM4ECA12CA1CA2 | |
| SCHEMBL9005609 | 0.82 | TTR (0.56) | TTRKDM4ECA12CA1CA2 | |
| SCHEMBL2910822 | 0.81 | CA12 (0.59) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL29723267 | 0.81 | CA12 (0.59) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL1014876 | 0.81 | TSHR (0.53) | TTRCA12CA1CA2CA4 | |
| SCHEMBL3795170 | 0.81 | HTT (0.45) | TTRKDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103992220-B | A kind of preparation method of roflumilast intermediate | INSTITUTE OF MATERIA MEDICA, SHANDONG ACADEMY OF MEDICAL SCIENCES (CN) | 2015-11-18 | — | — | CN | claimed |
| CN-103992220-A | Method for preparing roflumilast intermediate | INST OF MATERIA MEDICA SHANDONG ACADEMY OF MEDICAL SCIENCES | 2014-08-20 | — | — | CN | claimed |
| CN-102838533-A | Preparation method of roflumilast and key intermediate of roflumilast | BEIJING D VENTURE PHARM TECH | 2012-12-26 | — | — | CN | claimed |
| CN-103992220-B | A kind of preparation method of roflumilast intermediate | INSTITUTE OF MATERIA MEDICA, SHANDONG ACADEMY OF MEDICAL SCIENCES (CN) | 2015-11-18 | — | — | CN | disclosed |
| CN-103992220-A | Method for preparing roflumilast intermediate | INST OF MATERIA MEDICA SHANDONG ACADEMY OF MEDICAL SCIENCES | 2014-08-20 | — | — | CN | disclosed |
| CN-102838533-A | Preparation method of roflumilast and key intermediate of roflumilast | BEIJING D VENTURE PHARM TECH | 2012-12-26 | — | — | CN | disclosed |
| EP-1879884-B1 | AZOLE-BASED PHOSPHODIESTERASE INHIBITORS | RANBAXY LAB LTD (IN) | 2010-08-25 | — | — | EP | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-1879884-A1 | AZOLE-BASED PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117653-A1 | AZOLE-BASED PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | TTR 1817/4885KDM4E 1427/4885CA12 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.